Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2009

01-10-2009 | Original Paper

A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland

Authors: Hong He, Guanfu Chen, Liang Zhou, Yanmin Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2009

Login to get access

Abstract

Objective

To detect the levels of carcinoembryonic antigen (CEA) and carcinoma associated antigen CA-50 in the patients with oral or salivary malignant tumors.

Methods

The concentrations of salivary CEA and CA-50 were assayed in 80 patients of oral and salivary malignant tumors, 40 patients of benign tumors and 80 health controls. In 80 patients with malignant tumors, serum CEA and CA-50 were also assayed by enzyme-linked immunoabsorbent assay and immunoradiometric analysis, respectively.

Results

Salivary CEA and CA-50 levels were significantly higher in malignant tumors than in benign tumors and in health controls, respectively (P < 0.001). Only 7 cases and 3 cases of 80 patients with malignant tumors were found having increased serum CEA and CA-50 levels, respectively.

Conclusions

The measurement of CEA and CA-50 levels in saliva were more sensitive than in serum. This may be more useful as prognostic indicators in early diagnosis of oral and salivary malignant tumors.
Literature
go back to reference Airoldi M, Piantino P, Pacchioni D et al (1986) Gastrointestinal cancer-associated antigen (GICA) in oral carcinoma. Oral Surg Oral Med Oral Pathol 61(3):263CrossRefPubMed Airoldi M, Piantino P, Pacchioni D et al (1986) Gastrointestinal cancer-associated antigen (GICA) in oral carcinoma. Oral Surg Oral Med Oral Pathol 61(3):263CrossRefPubMed
go back to reference Angelov A, Klissarova A, Dikranian K (1996) Radioimmunological and immunohistochemical study of carcinoembryonic antigen in pleomorphic adenoma and mucoepidermoid carcinoma of the salivary glands. Gen Diagn Pathol 141(3–4):229–234PubMed Angelov A, Klissarova A, Dikranian K (1996) Radioimmunological and immunohistochemical study of carcinoembryonic antigen in pleomorphic adenoma and mucoepidermoid carcinoma of the salivary glands. Gen Diagn Pathol 141(3–4):229–234PubMed
go back to reference Cai W, Zheng H, Sheng J et al (1996) Initial study of joint detection of serum CA-50, CA19-9, CEA, and SA for diagnosis of gastric cancer. J Fujian Med Coll 30(3):239–242 Cai W, Zheng H, Sheng J et al (1996) Initial study of joint detection of serum CA-50, CA19-9, CEA, and SA for diagnosis of gastric cancer. J Fujian Med Coll 30(3):239–242
go back to reference Chao J, Song J, Xie C et al (1998) Diagnostic value of saliva and serum carbohydrate antigen CA-50 detection for parotid tumor. Yunnan Med 19(6):402–404 Chao J, Song J, Xie C et al (1998) Diagnostic value of saliva and serum carbohydrate antigen CA-50 detection for parotid tumor. Yunnan Med 19(6):402–404
go back to reference Charalabopoulos K, Karakosta A, Bablekos G et al (2007) CEA levels in serum and BAL in patients suffering from lung cancer. Med Oncol 24(2):219–225CrossRefPubMed Charalabopoulos K, Karakosta A, Bablekos G et al (2007) CEA levels in serum and BAL in patients suffering from lung cancer. Med Oncol 24(2):219–225CrossRefPubMed
go back to reference Chen G, Sun C, Yan J et al (1993) Clinical significance of saliva CEA detection for diagnosis of head and neck malignant tumor. J Pract Oncol 8(2):94–95 Chen G, Sun C, Yan J et al (1993) Clinical significance of saliva CEA detection for diagnosis of head and neck malignant tumor. J Pract Oncol 8(2):94–95
go back to reference Duraker N, Çelik AN (2001) The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 7(4):266–271CrossRef Duraker N, Çelik AN (2001) The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 7(4):266–271CrossRef
go back to reference Duraker N, Hot S, Polat Y et al (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95(2):142–147CrossRefPubMed Duraker N, Hot S, Polat Y et al (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95(2):142–147CrossRefPubMed
go back to reference Engarås B, Hafström L, Kewenter J et al (1999) Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA 242 during twelve months in men and women aged 60–64 years without malignant disease. Eur J Surg 165(2):110–116CrossRefPubMed Engarås B, Hafström L, Kewenter J et al (1999) Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA 242 during twelve months in men and women aged 60–64 years without malignant disease. Eur J Surg 165(2):110–116CrossRefPubMed
go back to reference Guo S, Luo Y, Wang H (1998) Diagnostic significance of five markers for malignant pleural effusion. J Chin Pract Med 18(5):279–280 Guo S, Luo Y, Wang H (1998) Diagnostic significance of five markers for malignant pleural effusion. J Chin Pract Med 18(5):279–280
go back to reference Gustafsson H, Franzén L, Grankvist K et al (1988) Glycoprotein tumour markers in head and neck neoplasms—a consecutive study on CA-50, CA 19-9, and CEA. J Cancer Res Clin Oncol 114(4):394–398CrossRefPubMed Gustafsson H, Franzén L, Grankvist K et al (1988) Glycoprotein tumour markers in head and neck neoplasms—a consecutive study on CA-50, CA 19-9, and CEA. J Cancer Res Clin Oncol 114(4):394–398CrossRefPubMed
go back to reference Inglot AD, Gelder F, Jerzy A (1998) Georgiades tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system. Biotherapy 11(1):27–37CrossRefPubMed Inglot AD, Gelder F, Jerzy A (1998) Georgiades tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system. Biotherapy 11(1):27–37CrossRefPubMed
go back to reference Japink D, Nap M, Leers M et al (2008) T1118 CEA in activated macrophages: a new prognostic or diagnostic factor for early detection of local recurrence of colorectal neoplasms? Gastroenterology 134(4):A-487CrossRef Japink D, Nap M, Leers M et al (2008) T1118 CEA in activated macrophages: a new prognostic or diagnostic factor for early detection of local recurrence of colorectal neoplasms? Gastroenterology 134(4):A-487CrossRef
go back to reference Kim DY, Kim HR, Shim JH et al (2000) Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol 74(3):185–192CrossRefPubMed Kim DY, Kim HR, Shim JH et al (2000) Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol 74(3):185–192CrossRefPubMed
go back to reference Koike H, Ichikawa D, Ikoma H et al (2004) Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol 87(4):182–186CrossRefPubMed Koike H, Ichikawa D, Ikoma H et al (2004) Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol 87(4):182–186CrossRefPubMed
go back to reference Koizumi F, Odagiri H, Fujimoto H et al (1992) Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer. Rinsho Byori 40(5):523–528PubMed Koizumi F, Odagiri H, Fujimoto H et al (1992) Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer. Rinsho Byori 40(5):523–528PubMed
go back to reference Marrelli D, Pinto E, De Stefano A et al (2001) Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol 78(4):253–258CrossRefPubMed Marrelli D, Pinto E, De Stefano A et al (2001) Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol 78(4):253–258CrossRefPubMed
go back to reference Murase R, Abe Y, Sumida T et al (2008) Serum autoantibody to sideroflexin 3 as a novel tumor marker for oral squamous cell carcinoma. China J Oral Maxillofac Surg 6(B05):205–206 Murase R, Abe Y, Sumida T et al (2008) Serum autoantibody to sideroflexin 3 as a novel tumor marker for oral squamous cell carcinoma. China J Oral Maxillofac Surg 6(B05):205–206
go back to reference Niklinski J, Furman M (1995) Clinical tumour markers in lung cancer. Eur J Cancer Prev 4(2):129–138CrossRefPubMed Niklinski J, Furman M (1995) Clinical tumour markers in lung cancer. Eur J Cancer Prev 4(2):129–138CrossRefPubMed
go back to reference Nilsson O, Johansson C, Glimelius B et al (1992) Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer 65(2):215–221PubMed Nilsson O, Johansson C, Glimelius B et al (1992) Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer 65(2):215–221PubMed
go back to reference Safi F, Bittner R, Roscher R et al (1986) The value of CEA and/or CA 19-9 serum course in the regional chemotherapy of liver metastases from colorectal carcinoma. J Cancer Res Clin Oncol 111(S1):S99 Safi F, Bittner R, Roscher R et al (1986) The value of CEA and/or CA 19-9 serum course in the regional chemotherapy of liver metastases from colorectal carcinoma. J Cancer Res Clin Oncol 111(S1):S99
go back to reference Sawant SS, Zingde SM, Vaidya MM (2008) Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 44(8):722–732CrossRefPubMed Sawant SS, Zingde SM, Vaidya MM (2008) Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 44(8):722–732CrossRefPubMed
go back to reference Seregni E, Coli A, Mazzucca N et al (2004) Circulating tumor marker in breast cancer. Eur J Nucl Med Mol Imaging 31:S15–S22CrossRefPubMed Seregni E, Coli A, Mazzucca N et al (2004) Circulating tumor marker in breast cancer. Eur J Nucl Med Mol Imaging 31:S15–S22CrossRefPubMed
go back to reference Wang Z, Xia C, Huang G et al (1998) Clinical significance of quantitative detection of CEA in salivary, gastric fluid, and blood. Abdom Surg 11(1):30 Wang Z, Xia C, Huang G et al (1998) Clinical significance of quantitative detection of CEA in salivary, gastric fluid, and blood. Abdom Surg 11(1):30
go back to reference Wang H, Feng X, An Y et al (1999) Clinical significance of saliva CEA and IgA detection for patients with oral-stomatology malignant tumor. J Pract Stomatol 15(6):447–448 Wang H, Feng X, An Y et al (1999) Clinical significance of saliva CEA and IgA detection for patients with oral-stomatology malignant tumor. J Pract Stomatol 15(6):447–448
go back to reference Zolotarevsky E, Kwon RS, Elta GH et al (2008) Fluid CEA level is more influential than DNA mutational analysis in guiding clinical management of pancreatic cystic lesions. Gastrointest Endosc 67(5):AB214–AB215CrossRef Zolotarevsky E, Kwon RS, Elta GH et al (2008) Fluid CEA level is more influential than DNA mutational analysis in guiding clinical management of pancreatic cystic lesions. Gastrointest Endosc 67(5):AB214–AB215CrossRef
Metadata
Title
A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland
Authors
Hong He
Guanfu Chen
Liang Zhou
Yanmin Liu
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0572-x

Other articles of this Issue 10/2009

Journal of Cancer Research and Clinical Oncology 10/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.